At a glance
- Originator Uriach
- Class Antiasthmatics
- Mechanism of Action Potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 21 Dec 2001 Discontinued-Preclinical for Asthma in Spain (Unknown route)
- 08 Jan 1996 An in vitro and in vivo study has been added to the pharmacodynamics section (company communication)
- 26 May 1995 New profile